Kymera Therapeutics Stock Analysis

Kymera Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The book value of Kymera Therapeutics was now reported as 13.79. The company has Price/Earnings To Growth (PEG) ratio of 0.64. Kymera Therapeutics recorded a loss per share of 2.34. The entity had not issued any dividends in recent years. Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodys own natural protein degradation system. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Kymera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 160 people. To find out more about Kymera Therapeutics contact the company at 857 285 5300 or learn more at https://www.kymeratx.com.

Kymera Therapeutics Investment Alerts

Kymera Therapeutics Upcoming and Recent Events

Kymera Largest EPS Surprises

View All Earnings Estimates

Kymera Therapeutics Environmental, Social, and Governance (ESG) Scores

Kymera Stock Institutional Investors

Note, although Kymera Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kymera Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.03 B.

Kymera Profitablity

The company has Profit Margin (PM) of (1.91) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (19.28) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $19.28.

Management Efficiency

Kymera Therapeutics has return on total asset (ROA) of (0.1538) % which means that it has lost $0.1538 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.26) %, meaning that it created substantial loss on money invested by shareholders. Kymera Therapeutics' management efficiency ratios could be used to measure how well Kymera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, Kymera Therapeutics' Net Tangible Assets are relatively stable compared to the past year. As of 11/29/2024, Non Current Assets Total is likely to grow to about 179 M, while Other Current Assets are likely to drop slightly above 6.6 M.

Technical Drivers

As of the 29th of November, Kymera Therapeutics secures the Standard Deviation of 3.08, mean deviation of 2.37, and Risk Adjusted Performance of 0.0028. Kymera Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kymera Therapeutics variance and skewness to decide if Kymera Therapeutics is priced some-what accurately, providing market reflects its recent price of 46.86 per share. Given that Kymera Therapeutics has information ratio of (0.05), we recommend you to check Kymera Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.

Kymera Therapeutics Price Movement Analysis

Kymera Therapeutics Insider Trading Activities

Kymera Therapeutics Outstanding Bonds

Kymera Therapeutics Predictive Daily Indicators

Kymera Therapeutics Corporate Filings

Kymera Therapeutics Forecast Models

Kymera Therapeutics' time-series forecasting models are one of many Kymera Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kymera Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kymera Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kymera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Kymera Therapeutics. By using and applying Kymera Stock analysis, traders can create a robust methodology for identifying Kymera entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kymera analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kymera analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Kymera Therapeutics stock analysis indicators help investors evaluate how Kymera Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kymera Therapeutics shares will generate the highest return on investment. By understating and applying Kymera Therapeutics stock analysis, traders can identify Kymera Therapeutics position entry and exit signals to maximize returns.

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.